MACOP-B and involved field radiation therapy is an effective therapy for primary mediastinal large B-cell lymphoma with sclerosis

51Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Purpose: To evaluate the clinical features of presentation and the response to two different third-generation regimens (F-MACHOP and MACOP-B) of primary mediastinal large B-cell lymphoma (MLBCL), a recently defined distinct clinicopathological entity of non-Hodgkin's lymphoma (NHL). Patients and methods: Thirty-seven consecutive patients with MLBCL, eight male and 29 female (F/M ratio 1:3.5) with a median age of 35 years, were enrolled in the present study. Thirty-five (94.5%) patients presented disease confined to thorax, with chest symptoms of a rapidly enlarging mass in the mediastinum in 70% and superior vena cava syndrome (SCVS) in 43% of these patients. The first 10 patients received F-MACHOP and the succeeding 27 patients MACOP-B chemotherapy, associated in 24 (88.8%) with involved field radiation therapy (IFRT). Gallium scan was routinely performed pre- and post- IFRT in 18 patients. Results: All 37 patients were assessable for response: 10 of 10 (100%) in the F-MACHOP and 26 of 27 (96.3%) in the MACOP-B group achieved overall responses (CR+PR). Three of 24 (12.5%) patients in PR after chemotherapy obtained CR after IFRT. Persistent Gallium avidity was observed in 16 patients after chemotherapy and in only four patients after IFRT. Thus far, four of the 10 F-MACHOP and two of the 26 MACOP-B responders have presented disease progression. The probability of progression-free survival (PFS) was 91% and 60% (P < 0.02) while overall survival (OS) was 93% and 70% (P = n.s.) at a mean follow-up of 27 and 52 months in the MACOP-B+IFRT and F-MACHOP groups, respectively. Conclusion: MACOP-B+IFRT has proved to be a highly effective and less toxic therapeutic approach for primary MLBCL and appears to be superior to other third-generation chemotherapy regimens.

References Powered by Scopus

A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group

6285Citations
N/AReaders
Get full text

MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma

621Citations
N/AReaders
Get full text

Large cell lymphoma of the mediastinum: a B‐cell tumour of probable thymic origin

174Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: Results of the Mabthera International Trial Group study

185Citations
N/AReaders
Get full text

Primary mediastinal large B-cell lymphoma (PMLBCL): Long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B

172Citations
N/AReaders
Get full text

Primary mediastinal B-cell lymphoma: A review of pathology and management

133Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Martelli, M. P., Martelli, M., Pescarmona, E., De Sanctis, V., Donato, V., Palombi, F., … Mandelli, F. (1998). MACOP-B and involved field radiation therapy is an effective therapy for primary mediastinal large B-cell lymphoma with sclerosis. Annals of Oncology, 9(9), 1027–1029. https://doi.org/10.1023/A:1008412009667

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

40%

Professor / Associate Prof. 3

30%

Researcher 3

30%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

64%

Agricultural and Biological Sciences 2

18%

Pharmacology, Toxicology and Pharmaceut... 1

9%

Computer Science 1

9%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 49

Save time finding and organizing research with Mendeley

Sign up for free